Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/28619
Conference/Presentation Title: | Expanding the phenotypic spectrum for alport syndrome and distinguishing phenocopies in genetic kidney disease. | Authors: | Mallett A.;Quinlan C.;Stark Z.;Jayasinghe K.;Kerr P.G. ;Ling R. | Monash Health Department(s): | Nephrology | Institution: | (Ling, Kerr, Jayasinghe) Department of Nephrology, Monash Medical Centre (Kerr, Jayasinghe) Monash University (Quinlan, Mallett, Stark, Jayasinghe) Murdoch Children's Research (Quinlan, Mallett, Stark, Jayasinghe) KidGen Collaborative, Australian Genomics Health Alliance (Stark) Department of Paediatrics, University of Melbourne (Stark) Victorian Clinical Genetics Services, Murdoch Children's Research Institute (Mallett) Kidney Health Service and Conjoint Renal Research Laboratory, Royal Brisbane and Women's Hospital (Mallett) Institute for Molecular Bioscience, Faculty of Medicine, University of Queensland (Quinlan) Department of Paediatric Nephrology, Royal Children's Hospital | Presentation/Conference Date: | 19-Jan-2021 | Copyright year: | 2020 | Publisher: | Blackwell Publishing | Publication information: | Nephrology. Conference: 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology, ANZSN 2020. Virtual. 25 (SUPPL 3) (pp 14), 2020. Date of Publication: December 2020. | Abstract: | Aim: To describe the phenotypic spectrum in patients with diagnostic type 4 collagen variants, and to determine phenocopies of Alport Syndrome (AS). Background(s): AS is the second most common form of genetic kidney disease (GKD). Recently, Medicare approved testing for the three genes associated with AS. Pursuing genetic diagnosis has important clinical implications. Method(s): We compared the suspected diagnosis prior to ES with the genomic diagnosis in patients with suspected AS from a cohort of 204 patients with suspected GKD. We also compared the suspected diagnosis to the molecular diagnosis in patients who were found to have type 4 collagen variants following ES. Result(s): 80/204(39%) had diagnostic variants in genes related to kidney disease. 26/80(33%) had diagnostic type 4 collagen variants. Most patients (n = 13) had autosomal dominant (AD) COL4A3/4 nephropathy. Eleven had X-Linked dominant AS and 2 had autosomal recessive AS. ES reclassified the diagnosis in 7/26(27%) of patients with type 4 collagen variants. Furthermore, 3 patients who had clinical symptoms suspicious of AS were found to have an alternate diagnosis following ES (2 had X-linked recessive Dent Disease and 1 had AD hypoparathyroidism, sensorineural deafness and renal dysplasia). Conclusion(s): ES revealed type 4 collagen variants in 6 patients with alternate clinical diagnoses suspected at referral. Three additional patients who were thought to have AS were subsequently given an alternate diagnosis. We suggest that AS is underdiagnosed, and testing should be considered in patients with a suspected monogenic cause of hematuria. We also highlight the importance of expanding analysis to additional genes in the evaluation of patients with suspected AS, in addition to those reimbursed by Medicare. ES allows easier subsequent reanalysis of genomic data. | Conference Start Date: | 2020-11-28 | Conference End Date: | 2020-12-02 | DOI: | http://monash.idm.oclc.org/login?url= http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/nep.13797 |
ISSN: | 1440-1797 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/28619 | Type: | Conference Abstract | Type of Clinical Study or Trial: | Observational study (cohort, case-control, cross sectional or survey) |
Appears in Collections: | Conferences |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.